efectos secundarios de glp 1 GLP-1: y Cómo Evitar el Efecto Rebote La automedicación con fármacos GLP-1

CKD affects over 850 million people worldwide and is projected to become the fifth leading cause of death by 2050, driven primarily by the obesity epidemic and rising type 2 diabetes prevalence

The phase 2 trial published in *NEJM* (2023) reported weight loss of up to 24.2% at 48 weeks at the 12mg dose, with some participants losing over 27%

Online photographs rarely provide this information

The product is also a sign that Bite and More is ready to dive into other areas of fitness, including the involvement of classic supplement formats.

The lack of rigorous human studies also means that data about side effects is missing as well as proper dosing regimens, Dekker said